Hinge Bio raises $30 million to progress B cell lupus therapy
By Helen Albert
Hinge Bio raises $30 million to progress B cell lupus therapy
Windward Bio launches to develop potential best-in-class antibody...
Alchemab and Lilly collaborate to discover and develop ALS therapies
MaaT Pharma’s microbiome therapy scores phase 3 win
Adcentrx launches Phase 1 study for its next-generation ADC...
BrainChild Bio advances development of CAR T therapy for pediatric...
→
→
→
→